IndustryCompany release

Cibus reports Latin American rice trait trials succeeded as biofragrance manufacturing begins

🇺🇸 Cibus, Inc. (CBUS) · Thu 12 Nov 2026

The US gene-editing company also launched a partner-funded Indian Mustard programme and cut nine-month operating cash use by about 19%, to $30.2 million.

Cibus (Nasdaq: CBUS) published its third-quarter 2026 results on 12 November 2026. The company said its herbicide-tolerance Rice traits performed well in field trials in Latin America.

The traits are now being tested in the own varieties of customer Interoc in Ecuador. The source does not give trial data or a commercial timeline.

Cibus also said it has started manufacturing its first two biofragrance ingredients, and that its partner has approved both for use. A partner-funded Indian Mustard programme has also begun.

On finances, operating cash use for the first nine months fell by about 19% to $30.2 million. Cibus still expects to leave 2026 at an annualised net cash usage rate of roughly $35 million.

What it means for your team

  • Teams tracking gene-edited crops should note that the Rice trait work has moved from Latin American field trials into a customer's own varieties in Ecuador.
  • Any regulatory status of the traits in Ecuador or other markets was not stated in the available material and should be checked directly.
  • The biofragrance ingredients are now in manufacturing with partner approval, so the programme has moved beyond development.
  • Cibus's year-end guidance of roughly $35 million annualised net cash usage is unchanged.

Company's press release (SEC filing): Cibus, Inc. ↗

Article written by VigiEye from the official source (Cibus, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →